COMPANY UPDATE

2026. 7. 31

Scan to go to
Research Center report database

Innovation Team

Keunhee Seo, Ph.D.
Team Leader
keunhee.seo@samsung.com

Suhan Shin
Research Associate
shn.shin@samsung.com

Celltrion (068270)

New products driving structural growth

- Celltrion's operating results should reflect accelerating leverage from rapid market adoption of new products and the recognition of CMO earnings at its US plant (Branchburg).

WHAT'S THE STORY?

2Q review: Celltrion reported 2Q consolidated sales of KRW1.39t (+45% y-y and +21.7% q-q) and operating profit of KRW451.8b (+86.3% y-y and +40.4% q-q), for an operating margin of 32.4%. Sales from five newly launched products surged to KRW314.4b (+369% y-y and +48.8% q-q), increasing their share of total revenue to 65%, with leverage effects in full swing. Zymfentra sales rose to KRW46.7b (+107% y-y and -11.6% q-q), driven by higher prescription volumes and unit sales, though this was partially offset by the recognition of gross-to-net (GTN) rebate. The company's US plant in Branchburg resumed operations in March, with revenue recognized in 2Q; however, operating profit from CMO activities was not reflected in 2Q and should be recognized from 2H.

2026 Outlook: We expect full-year 2026 sales of KRW5.48t (+31.6% y-y) and operating profit of KRW1.88t (+61.3% y-y). Omlyclo (first-mover) and Stoboclo (listed in 3 US PBM formularies out of the top 5) should emerge as key growth drivers. Omlyclo's 300mg formulation is scheduled for launch in 2H26 in the US. Zymfentra's collaboration with Pfizer is expected to be finalized by 3Q, with synergies fully reflected starting in 4Q.

(Continued on the next page)

AT A GLANCE

BUY

Target price	KRW260,000	36.8%
Current price	**KRW190,000**	
Market cap	KRW44.2t/USD30.7b	
Shares (float)	232,553,706 (65.2%)	
52-week high/low	KRW236,862/KRW159,400	
Avg daily trading value (60-day)	KRW129.6b/ USD90.2m	

ONE-YEAR PERFORMANCE

	1M	6M	12M
Celltrion (%)	9.6	-5.1	10.7
Vs Kospi (%pts)	66.1	-11.3	-35.6

KEY CHANGES

(KRW)	New	Old	Diff
Recommend.	BUY	BUY	
Target price	260,000	260,000	0.0%
2026E EPS	6,573	6,331	3.8%
2027E EPS	7,235	7,170	0.9%

SAMSUNG vs THE STREET

No of estimates	18
Target price	265,398
Recommendation	4.0

※ Rating: 4 < → BUY, 3 = HOLD, 2 > → SELL

SUMMARY 2Q RESULTS

(KRWb)	2Q26	Chg (% y-y)	Chg (% q-q)	Diff (%) Samsung	Diff (%) Consensus
Sales	1,393.7	45.0	21.7	7.2	11.7
Operating profit	451.8	86.3	40.4	5.1	12.5
Pre-tax profit	457.8	773.7	5.9	12.3	12.3
Net profit (controlling)	370.2	504.9	7.0	17.6	12.5
Margins (%)					
Operating profit	32.4				
Pre-tax profit	32.8				
Net profit (controlling)	26.6				

Source: Company data, FnGuide, Samsung Securities estimates

VALUATION SUMMARY

	2025	2026E	2027E
Valuations (x)			
P/E	40.7	28.9	26.3
P/B	2.3	2.3	2.1
EV/EBITDA	30.5	20.7	17.6
Div yield (%)	0.4	0.4	0.4
EPS growth (% y-y)	148.8	55.1	10.1
ROE (%)	5.9	8.6	8.6
Per-share data (KRW)			
EPS	4,238	6,573	7,235
BVPS	75,020	82,493	89,134
DPS	715	715	715

Maintaining BUY and target price: We maintain our 12-month target price of KRW260,000 (derived by applying a 25x EV/EBITDA multiple to our 12-month forward EBITDA estimate of KRW2.4t). Structural earnings growth should continue well into 2H26, backed by higher-margin product sales and the beginning of US CMO sales. Celltrion has a proven track record of rapid market adoption for new launches. The sequential rollout of follow-on pipeline products—including Herzuma SC in 2027, followed by Ocrevus, Keytruda, and Darzalex biosimilars from 2028—should be a key determinant of long-term revenue growth.

Income statement

Year-end Dec 31 (KRWb)	2024	2025	2026E	2027E	2028E
Sales	**3,557**	**4,162**	**5,476**	**6,050**	**6,685**
Cost of goods sold	1,876	1,695	2,008	2,093	2,313
Gross profit	**1,682**	**2,467**	**3,468**	**3,957**	**4,372**
Gross margin (%)	47.3	59.3	63.3	65.4	65.4
SG&A expenses	1,190	1,299	1,583	1,745	1,857
Operating profit	**492**	**1,168**	**1,885**	**2,212**	**2,515**
Operating margin (%)	13.8	28.1	34.4	36.6	37.6
Non-operating gains (losses)	**84**	**-15**	**50**	**-61**	**-7**
Financial profit	57	60	49	60	85
Financial costs	80	96	104	93	92
Equity-method gains (losses)	-12	-14	2	0	0
Other	120	36	103	-29	0
Pre-tax profit	**576**	**1,154**	**1,935**	**2,151**	**2,508**
Taxes	157	122	405	451	439
Effective tax rate (%)	27.3	10.6	20.9	21.0	17.5
Profit from continuing operations	419	1,031	1,558	1,700	2,069
Profit from discontinued operations	0	0	0	0	0
Net profit	**419**	**1,031**	**1,558**	**1,700**	**2,069**
Net margin (%)	11.8	24.8	28.5	28.1	30.9
Net profit (controlling interests)	423	1,030	1,545	1,683	2,048
Net profit (non-controlling interests)	-4	2	13	17	21
EBITDA	910	1,456	2,180	2,481	2,758
EBITDA margin (%)	25.6	35.0	39.8	41.0	41.3
EPS (parent-based) (KRW)	1,703	4,238	6,573	7,235	8,808
EPS (consolidated) (KRW)	1,688	4,245	6,629	7,308	8,897
Adjusted EPS (KRW)*	1,703	4,238	6,573	7,235	8,808

Balance sheet

Year-end Dec 31 (KRWb)	2024	2025	2026E	2027E	2028E
Current assets	**5,584**	**6,205**	**8,568**	**10,559**	**12,845**
Cash & equivalents	996	1,119	2,873	4,388	6,027
Accounts receivable	1,215	1,790	1,967	2,121	2,343
Inventories	2,766	2,803	3,039	3,275	3,619
Other current assets	607	492	689	775	856
Fixed assets	**15,471**	**16,130**	**16,255**	**16,001**	**15,771**
Investment assets	161	170	180	195	209
Tangible assets	1,245	1,703	1,651	1,539	1,438
Intangible assets	13,702	13,778	13,901	13,745	13,602
Other long-term assets	364	479	523	523	523
Total assets	**21,055**	**22,335**	**24,823**	**26,560**	**28,617**
Current liabilities	**3,187**	**4,454**	**5,265**	**5,456**	**5,593**
Accounts payable	75	125	109	117	130
Short-term debt	1,989	3,239	3,364	3,364	3,364
Other current liabilities	1,123	1,090	1,792	1,975	2,099
Long-term liabilities	**288**	**529**	**536**	**546**	**560**
Bonds & long-term debt	87	387	387	387	387
Other long-term liabilities	201	141	149	159	173
Total liabilities	**3,475**	**4,982**	**5,801**	**6,002**	**6,153**
Owners of parent equity	**17,439**	**17,208**	**18,869**	**20,389**	**22,273**
Capital stock	221	239	239	239	239
Capital surplus	14,828	14,215	14,234	14,234	14,234
Retained earnings	3,744	4,407	5,788	7,307	9,192
Other	-1,353	-1,653	-1,392	-1,392	-1,392
Non-controlling interests' equity	**141**	**144**	**153**	**170**	**191**
Total equity	**17,580**	**17,353**	**19,023**	**20,559**	**22,464**
Net debt	1,064	2,500	814	-721	-2,452

Cash flow statement

Year-end Dec 31 (KRWb)	2024	2025	2026E	2027E	2028E
Cash flow from operations	**902**	**646**	**1,887**	**1,746**	**1,915**
Net profit	419	1,031	1,558	1,700	2,069
Non-cash profit and expenses	649	553	703	753	689
Depreciation	73	93	124	112	101
Amortization	346	195	171	156	143
Other	231	266	408	484	446
Changes in A/L from operating activities	-21	-495	-34	-255	-404
Cash flow from investments	**-169**	**-860**	**-117**	**40**	**66**
Change in tangible assets	-135	-108	-35	0	0
Change in financial assets	47	30	-42	-20	-19
Other	-81	-782	-41	60	85
Cash flow from financing	**-353**	**339**	**-153**	**-256**	**-328**
Change in debt	318	1,531	109	0	-73
Change in equity	38	-604	19	0	0
Dividends	-104	-154	-164	-163	-163
Other	-605	-434	-117	-93	-92
Change in cash	432	123	1,754	1,515	1,639
Cash at beginning of year	565	996	1,119	2,873	4,388
Cash at end of year	996	1,119	2,873	4,388	6,027
Gross cash flow	**1,068**	**1,585**	**2,261**	**2,452**	**2,758**
Free cash flow	**767**	**538**	**1,851**	**1,746**	**1,915**

Note: *Excluding one-off items;
**Fully diluted, excluding one-off items;
***From companies subject to equity-method valuation
Source: Company data, Samsung Securities estimates

Financial ratios

Year-end Dec 31	2024	2025	2026E	2027E	2028E
Growth (%)					
Sales	63.4	17.0	31.6	10.5	10.5
Operating profit	-24.5	137.5	61.3	17.4	13.7
Net profit	-22.4	146.2	51.0	9.1	21.7
Adjusted EPS**	-46.6	148.8	55.1	10.1	21.7
Per-share data (KRW)					
EPS (parent-based)	1,703	4,238	6,573	7,235	8,808
EPS (consolidated)	1,688	4,245	6,629	7,308	8,897
Adjusted EPS**	1,703	4,238	6,573	7,235	8,808
BVPS	74,502	75,020	82,493	89,134	97,373
DPS (common)	657	715	715	715	715
Valuations (x)					
P/E***	101.1	40.7	28.9	26.3	21.6
P/B***	2.3	2.3	2.3	2.1	2.0
EV/EBITDA	46.0	30.5	20.7	17.6	15.2
Ratios (%)					
ROE	2.5	5.9	8.6	8.6	9.6
ROA	2.0	4.8	6.6	6.6	7.5
ROIC	1.9	5.5	7.6	9.0	10.6
Payout ratio	36.4	15.9	10.6	9.7	8.0
Dividend yield (common)	0.4	0.4	0.4	0.4	0.4
Net debt to equity	6.1	14.4	4.3	-3.5	-10.9
Interest coverage (x)	6.5	15.5	19.6	23.8	27.4

Compliance notice

- As of 7/30 2026, the covering analyst(s) did not own any shares, or debt instruments convertible into shares, of any company covered in this report.
- As of 7/30 2026, Samsung Securities' holdings of shares and debt instruments convertible into shares of each company covered in this report would not, if such debt instruments were converted, exceed 1% of each company's outstanding shares.
- This report has been prepared without any undue external influence or interference, and accurately reflects the views of the analyst(s) covering the company or companies herein.
- All material presented in this report, unless specifically indicated otherwise, is under copyright to Samsung Securities.
- Neither the material nor its content (including copies) may be altered in any form, or by any means transmitted, copied, or distributed to another party, without prior express written permission from Samsung Securities.
- This memorandum is based upon information available to the public. While we have taken all reasonable care to ensure its reliability, we do not guarantee its accuracy or completeness. This memorandum is not intended to be an offer, or a solicitation of any offer, to buy or sell the securities mentioned herein. Samsung Securities shall not be liable whatsoever for any loss, direct or consequential, arising from the use of this memorandum or its contents. Statements made regarding affiliates of Samsung Securities are also based upon publicly available information and do not necessarily represent the views of management at such affiliates.
- This material has not been distributed to institutional investors or other third parties prior to its publication.

Target price changes in past two years



Rating changes over past two years (adjusted share prices)

Date	2024/4/29	12/31	2025/2/11	5/12	6/19	7/21	2026/1/2	2/5	7/3
Recommendation	BUY	BUY	BUY	BUY	BUY	BUY	BUY	BUY	BUY
Target price (KRW)	219218	219218	211164	201983	200165	209697	219228	247823	247823
Gap* (average)	-24.55	-24.16	-24.51	-27.24	-18.76	-19.27	-8.10	-22.88	
(max or min)**	-16.40	-22.31	-17.70	-22.65	-14.10	-10.86	-3.91	-4.42	

Note: * [(average, maximum, or minimum share price over duration of target price minus target price) / target price] x 100%
** Maximum/minimum share price if new target is higher/lower than market close on the business day prior to target price change

Samsung Securities uses the following investment ratings*

Company

BUY Expected to increase in value by 15% or more within 12 months and is highly attractive within sector

HOLD Expected to increase/decrease in value by less than 15% within 12 months

SELL Expected to decrease in value by 15% or more within 12 months

Industry

OVERWEIGHT Expected to outperform market by 5% or more within 12 months

NEUTRAL Expected to outperform/underperform market by less than 5% within 12 months

UNDERWEIGHT Expected to underperform market by 5% or more within 12 months

Note: *Effective Jul 27, 2023, BUY, HOLD, and SELL criteria are based on expectations of share-price moves of 15% or more within 12 months

Percentage of ratings in 12 months prior to 2026.06.30

BUY (85.5%)·HOLD (14.5%)·SELL (0%)

Global Disclosures & Disclaimers

General

This research report is for information purposes only. It is not and should not be construed as an offer or solicitation of an offer to purchase or sell any securities or other financial instruments or to participate in any trading strategy. This report does not provide individually tailored investment advice. This report does not take into account individual client circumstances, objectives, or needs and is not intended as recommendations of particular securities, financial instruments or strategies to any particular client. The securities and other financial instruments discussed in this report may not be suitable for all investors. The recipient of this report must make its own independent decisions regarding any securities or financial instruments mentioned herein and investors should seek the advice of a financial adviser.

This report may not be altered, reproduced, distributed, transmitted or published in whole or in part for any purpose. References to "Samsung Securities" are references to any company in the Samsung Securities, Co., Ltd. group of companies.

Samsung Securities and/or other affiliated companies, its and their directors, officers, representatives, or employees may have long or short positions in any of the securities or other financial instruments mentioned in this report or of issuers described herein and may purchase and/or sell, or offer to purchase and/or sell, at any time, such securities or other financial instruments in the open market or otherwise, as either a principal or agent. Any pricing of securities or other financial instrument contained herein is as of the close of market for such day, unless otherwise stated. Opinions and estimates contained herein constitute our judgment as of the date of this report and are subject to change without notice.

The information provided in this report is provided "AS IS". Although the information contained herein has been obtained from sources believed to be reliable, no representation or warranty, either expressed or implied, is provided by Samsung Securities in relation to the accuracy, completeness or reliability of such information or that such information was provided for any particular purpose and Samsung Securities expressly disclaims any warranties of merchantability or fitness for a particular purpose. Furthermore, this report is not intended to be a complete statement or summary of the securities, markets or developments referred to herein.

Samsung Securities does not undertake that investors will obtain any profits, nor will it share with investors any investment profits. Samsung Securities, its affiliates, or any of its and their affiliates, directors, officers, employees or agents disclaim any and all responsibility or liability whatsoever for any loss (direct or consequential) or damage arising out of the use of all or any part of this report or its contents or otherwise arising in connection therewith. Information and opinions contained herein are subject to change without notice. Past performance is not indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security or financial instrument mentioned in this report. For investment advice, trade execution or other enquiries, clients should contact their local sales representative. Any opinions expressed in this report are subject to change without notice and may differ or be contrary to opinions expressed by other business areas or groups of Samsung Securities. Any analysis contained herein is based on numerous assumptions. Different assumptions may result in materially different results. Samsung Securities is under no obligation to update or keep current the information contained herein. Samsung Securities relies on information barriers to control the flow of information contained in one or more areas or groups within Samsung Securities into other areas or groups of Samsung Securities. Any prices stated in this report are for information purposes only and do not represent valuations for individual securities or other financial instruments. Samsung Securities makes no representation that any transaction can or could have been effected at those prices and any prices contained herein may not reflect Samsung Securities' internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions by Samsung Securities or any other source may yield substantially different results. Additional information is available upon request.

For reports to be distributed to US:

Securities research is prepared, issued and exclusively distributed by Samsung Securities Co., Ltd., an organization licensed with the Financial Supervisory Service of South Korea. This research may be distributed in the United States only to major institutional investors as defined in Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended, and may not be circulated to any other person otherwise. All transactions by U.S. investors involving securities discussed in this report must be effected through Samsung Securities (America) Inc., a broker-dealer registered with the U.S. Securities & Exchange Commission and a member of the Financial Industry Regulatory Authority/SIPC, and not through any non-U.S. affiliate thereof. The analysts listed [on the front of this report] are employees of Samsung Securities Co., Ltd., or a non-U.S. affiliate thereof, and are not registered/qualified as research analysts under applicable U.S. rules and regulations and may not be subject to U.S. restrictions on communications with covered companies, public appearances, and trading securities held by a research analyst account.

For reports to be distributed to UK:

This report is not an invitation nor is it intended to be an inducement to engage in investment activity for the purpose of section 21 of the Financial Services and Markets Act 2000 of the United Kingdom ("FSMA"). To the extent that this report does constitute such an invitation or inducement, it is directed only at (i) persons who are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 (as amended) of the United Kingdom (the "Financial Promotion Order"); (ii) persons who fall within Articles 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Promotion Order; and (iii) any other persons to whom this report can, for the purposes of section 21 of FSMA, otherwise lawfully be made (all such persons together being referred to as "relevant persons").

Any investment or investment activity to which this report relates is available only to relevant persons and will be engaged in only with relevant persons. Persons who are not relevant persons must not act or rely on this report.

For reports to be distributed to Korea:

This report is for private circulation only, not for sale, and is issued and distributed only to persons permitted under the laws and regulations of Korea.

For reports to be distributed to Singapore:

This report is provided pursuant to the financial advisory licensing exemption under Regulation 27(1)(e) of the Financial Advisers Regulation of Singapore and accordingly may only be provided to persons in Singapore who are "institutional investors" as defined in Section 4A of the Securities and Futures Act, Chapter 289 of Singapore. This report is intended only for the person to whom Samsung Securities has provided this report and such person may not send, forward or transmit in any way this report or any copy of this report to any other person.

Analyst certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of such analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research report. The analyst(s) principally responsible for the preparation of this research report receives compensation based on determination by research management and senior management (not including investment banking), based on the overall revenues, including investment banking revenues of Samsung Securities Co., Ltd. and its related entities and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations.

Samsung Securities

SAMSUNG SECURITIES

Samsung Electronics Bldg., 11, 74-gil,
Seochodae-ro, Seocho-gu, Seoul, Korea 06620
Tel: 02 2020 8000 / www.samsungpop.com

Family Center: 1588 2323

Voice Of Customer: 080 911 0900

**For more information,
please call our sales representatives:**

LONDON

Samsung Securities Europe Limited
1st Floor, 30 Gresham Street, London EC2V 7PG UK
Tel. 44-207-776-4311
Fax. 44-203-837-9219

NEW YORK

Samsung Securities America Limited
1330 Avenue of the Americas. 10th Floor. New York,
NY 10019
Tel: 1-212-972-2454
Fax: 1-212-972-2704

HONG KONG

Samsung Securities (Asia) Limited
Suite 4511, Two International Finance Center,
8 Finance Street, Central, Hong Kong
Tel: 852-3411-3608
Fax: 852-2114-0290

BEIJING

Samsung Securities Beijing Representative Office
Rm. 910, The Exchange Building No 118 JianGuo Lu, Chao
Yang District, Beijing, China
Tel: 86-10-6522-1855 (extension 7891)
Fax: 86-10-6522-1855 (extension 7889)

TOKYO

Samsung Securities Tokyo Representative Office
#106-8532 19F, Roppongi T-Cube 3-1-1,
Roppongi Minato-ku Tokyo, Japan
Tel: 81-3-6333-2952
Fax: 81-3-6333-2953